Show simple item record

dc.contributor.authorDutt, Amit
dc.contributor.authorSalvesen, Helga B.
dc.contributor.authorChen, Tzu-Hsiu
dc.contributor.authorRamos, Alex H.
dc.contributor.authorOnofrio, Robert C.
dc.contributor.authorHatton, Charlie
dc.contributor.authorNicoletti, Richard
dc.contributor.authorWinckler, Wendy
dc.contributor.authorGrewal, Rupinder
dc.contributor.authorHanna, Megan
dc.contributor.authorWyhs, Nicolas
dc.contributor.authorZiaugra, Liuda
dc.contributor.authorRichter, Daniel J.
dc.contributor.authorTrovik, Jone
dc.contributor.authorEngelsen, Ingeborg B.
dc.contributor.authorStefansson, Ingunn M.
dc.contributor.authorFennell, Tim
dc.contributor.authorCibulskis, Kristian
dc.contributor.authorZody, Michael C.
dc.contributor.authorAkslen, Lars A.
dc.contributor.authorGabriel, Stacey
dc.contributor.authorWong, Kwok-Kin
dc.contributor.authorSellers, William R.
dc.contributor.authorMeyerson, Matthew
dc.contributor.authorGreulich, Heidi
dc.date.accessioned2019-10-13T16:03:19Z
dc.date.issued2008
dc.identifier.citationDutt, A., H. B. Salvesen, T.-H. Chen, A. H. Ramos, R. C. Onofrio, C. Hatton, R. Nicoletti, et al. 2008. “Drug-Sensitive FGFR2 Mutations in Endometrial Carcinoma.” Proceedings of the National Academy of Sciences 105 (25): 8713–17. doi:10.1073/pnas.0803379105.
dc.identifier.issn0027-8424
dc.identifier.issn0744-2831
dc.identifier.issn1091-6490
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41542794*
dc.description.abstractOncogenic activation of tyrosine kinases is a common mechainism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.
dc.language.isoen_US
dc.publisherNational Academy of Sciences
dash.licenseLAA
dc.titleDrug-sensitive FGFR2 mutations in endometrial carcinoma
dc.typeJournal Article
dc.description.versionVersion of Record
dc.relation.journalProceedings of the National Academy of Sciences of the United States of America
dash.depositing.authorGreulich, Heidi E.::c15bca5202cf531c26bf896ddeaa5e65::600
dc.date.available2019-10-13T16:03:19Z
dash.workflow.comments1Science Serial ID 90210
dc.identifier.doi10.1073/pnas.0803379105
dash.source.volume105;25
dash.source.page8713


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record